very often don't have time to devote employees to outside projects, such as IMI. Our editorial attempted to highlight the problem that the innovative agenda of EFPIA members may not be as broad as the innovative agenda put forward by less established and smaller companies who seek to disrupt conventional approaches. For example, it is clear that cells derived from human induced pluripotent stem cells offer considerable potential in drug discovery screens and safety assessment, and this has been demonstrated by the investment by the pharmaceutical industry in these approaches in recent years. But what about the potential of such products as experimental therapies in themselves? Clearly, a focus for many SMEs and academic groups but not a major focus for many major pharmaceutical companies. Perhaps IMI could play a role in moving such unconventional approaches forward, especially if the funding and expertise from EU and EFPIA could be used to help SMEs focus their efforts to address the formidable manufacturing, regulatory and reimbursement issues that cell therapies face before reaching the market.
biomarker candidates for drug-induced injury of the kidney, the liver and the vascular system and established a generic strategy to qualify biomarkers 4 , whereas the eTOX consortium (http://www.e-tox. net/consortium.html), which includes four IT solution SMEs, developed an innovative multi-scale modeling strategy allowing the in silico prediction of drug effects on the heart using electrocardiogram simulations 5 . In parallel, four education and training projects are running, covering different areas of pharmaceutical sciences, including pharmacovigilance, of direct relevance to industry and regulatory authorities. Therefore, the alarmist and negative description of IMI reported in this journal does not reflect reality.
In an era where biopharmaceutical companies rely more and more on noncompetitive research and open collaboration to develop new models for drug development, IMI offers unique opportunities for academic groups and SMEs interested in translating results of their endeavors into innovative therapies. The update of the IMI Scientific Research Agenda has just been completed and will result in a series of even more ambitious projects based on sharing of data and know-how to address major unmet medical needs.
The currently running 4 th Call for Proposals ( Table 1 ) already contains two 'Think Big' projects with a transformational potential: the first aims at developing a European framework for patient-level health information, which will be exploited for investigations on major diseases in adult and pediatric populations; the second will focus on the use of induced pluripotent stem cells derived from patients as innovative tools for drug discovery and safety assessment. The budget of each project will be around €50 ($70) million, with equal contributions from the European Commission and companies in EFPIA (the European Federation of Pharmaceutical Industries and Associations), the latter in the form of inkind contributions.
More than ever, the European Commission and EFPIA are determined to stimulate industry, including SMEs, and academia to collaborate on large-scale 'game changing' IMI projects to foster scientific talents and strengthen the ecosystem of pharmaceutical research across the European Union, for the ultimate benefit of patients. Biosimilars-why terminology matters opened up the possibility of developing biological products similar to these original products and to rely for licensing, in part, on the extensive knowledge gained with the originator products. Although copy versions of original biopharmaceuticals are already available in different parts of the world, there are no consistent worldwide requirements for their registration. In Europe, the EMA's Committee for Medicinal Products for Human Use (CHMP) is responsible for the scientific assessment of human medicines that follow the European 'centralized procedure of marketing authorization' . According to this legislation, all recombinant proteins must undergo this route for licensing 1 . As most biosimilars are recombinant proteins, they usually have to follow this centralized route.
According to the EU, a biosimilar medicinal product is a copy version of an already authorized biological medicinal product (the reference product) with demonstrated similarity in physicochemical characteristics, efficacy and safety, based on To the Editor: As members of the Biosimilar Medicinal Products Working Party (BMWP) at the European Medicines Agency (EMA; London), we would like to draw readers' attention to problems arising from imprecise usage of the term biosimilar (similar biological medicinal product) in the literature. We have repeatedly noticed misinterpretations of the biosimilar concept as well as inconsistent use of terminology and are concerned about potential implications of this, such as negative perception and impaired acceptance of biosimilars among prescribing physicians and patients. Here we outline the scientific principles underlying the biosimilar concept in the European Union (EU; Brussels). We also address problems in terminology in the context of global emergence of copy biologicals (including 'true' biosimilars) and 'biobetters' , and the potential for unjustified concerns about the efficacy and safety of biosimilars in their stricter sense.
The recent expiry of data protection or patents for the first biopharmaceuticals has a comprehensive comparability exercise 2, 3 . Biological medicinal products are derived from living cells or organisms and consist of relatively large and highly complex molecular entities that are often difficult to fully characterize by currently available analytical methods. Because of the inherent variability of the biological system used as manufacturing process, the resulting biological product will also display a certain degree of variability ('microheterogeneity').
Developers of biosimilars usually do not have access to either the originator companies' proprietary data, including details on the manufacturing process, or the active ingredient of the reference medicine. Therefore, they need to engineer their own manufacturing process that is capable of manufacturing a product as similar as possible to the reference product.
Because of unavoidable differences in the manufacturing process, which may include the use of different expression systems, fermentation and purification processes, as well as different excipients, the quality attributes of the biosimilar and the reference medicinal products will not be strictly identical. Such variability may not be a matter of concern but rather is a scientific fact that has been accepted by the scientific and regulatory community since the introduction of biotech for the production of biological medicines.
As a biosimilar is highly unlikely to be identical to its reference product, the standard 'generic' approach (that is, demonstration of bioequivalence in comparative bioavailability studies, established for small chemically derived and easily characterized molecules) is not sufficient for the development, regulatory assessment and licensing of such a product. For this reason, we argue that the term biogeneric is scientifically incorrect and should not be used for a biosimilar.
In the EU, any biosimilar submitted for approval is assessed through a thorough comparability exercise with the reference product, including a comparison of the quality attributes and followed by comparative nonclinical studies, if considered necessary for safety reasons, and clinical studies, to ensure close resemblance in physicochemical characteristics, safety and efficacy. It should be noted that a comparability exercise is also required for originator biological medicinal products when changes to the manufacturing process are made 4 . Indeed, such changes are frequently introduced throughout a product's lifecycle (e.g., to improve the quality or to increase the yield of the product). As a consequence, the quality profile of the biological product may evolve over its life cycle but would still be considered as comparable to the product before changes were made as long as relevant impact on safety and efficacy has been excluded with sufficient confidence 5 .
The scientific principles underlying the comparability exercise required for changes in the manufacturing process of a given biological product and for the development of a biosimilar product are the same. Even so, data requirements for the latter are higher and, at least in the EU, always include clinical studies because, due to the completely independent manufacturing processes, some differences between the biosimilar and the reference product can be expected, and the potential impact of these differences on safety and efficacy cannot be predicted from analytical assessment alone. Therefore, biosimilars approved in the EU have always been clinically tested in addition to being characterized physicochemically and biologically.
As for any biosimilar, the biological reference medicine will have been authorized and in clinical use for several years and a large body of knowledge on its efficacy and safety will be available. A biosimilar is intended to be used at the same dose(s) and dosing regimen(s) to treat the same disease(s) as the reference product. Therefore, the focus of biosimilar development is not to establish patient benefit per se-this has already been done for the reference product-but to convincingly demonstrate similarity to the reference product as the basis for relying, in part, on efficacy and safety experience gained with the reference product. The various general and product class-specific EU guidelines for biosimilars define the nonclinical and clinical studies that need to be carried out to show that the biosimilar medicine is indeed similar and as safe and effective as the biological reference medicine 2 . A repetition of the entire development program of the reference product would, on scientific grounds, not add relevant information (e.g., phase 2 proofof-concept studies) and thus could even be considered unethical.
Clinical biosimilarity is established by use of a 'sensitive' clinical test model, able to detect potential differences between the biosimilar and the reference product. For example, differences in the efficacy of two insulins would be more likely to be detected Unknown whether and which physicochemical differences exist compared to other biologicals of the same product class.
Clinical comparison alone usually not sensitive enough to pick up differences of potential relevance. Therefore, extrapolation of clinical indications problematic.
Second-generation (next-generation) biological/biologic
Biobetter Biological that has been structurally and/or functionally altered to achieve an improved or different clinical performance.
Usually stand-alone developments with a full development program.
Clear (and intended) differences in the structure of the active substance, and most probably different clinical behavior due to, for example, different potency or immunogenicity.
From a regulatory perspective, a claim for 'better' would have to be substantiated by data showing a clinically relevant advantage over a first-or previous-generation product.
a Comparable terms defined by the same/similar scientific principles include the WHO's 'similar biotherapeutic products' and Health Canada's (Toronto) 'subsequent-entry biologicals'.
World Health Organization (WHO; Geneva) definition is "deliberately and fraudulently mislabeled with respect to identity and/or source. " 14 . Counterfeiting has recently, for example, been reported for epoetins 15, 16 . For these reasons, we suggest that any copy version of a therapeutic protein, which has not been developed and assessed in line with the scientific principles of a strictly comparative development program against a reference product, should not be termed biosimilar. We do not wish to imply that other products are of lower quality, efficacy or safety, but simply that they may not qualify as biosimilars according to the understanding of this term in the EU and potentially other regions, and thus may require different terminology to enable a clear distinction between the different products.
Using a consistent and clear terminology will prevent confusion between biosimilars and other copy versions of original biological medicinal products, and ensure their safe use. Indeed, recently, the WHO has adopted a 'Guideline on evaluation of similar biotherapeutic products' to provide globally acceptable principles for licensing of biotherapeutic products that are claimed to be similar to biotherapeutic products of assured quality, safety and efficacy, based on a reduced data package 17 . Despite the use of a slightly different term (that is, "similar biotherapeutic product"), the scientific principles laid down in this document are generally in line with the EU requirements. We expect that this WHO guideline will facilitate the employment of sound global standards for the development and licensing of similar biotherapeutic products.
Of particular note, the US Food and Drug Administration (FDA) previously used the informal term 'follow-on protein products' to refer to "proteins and peptides that are intended to be sufficiently similar to a product already approved under the Federal Food, Drug, and Cosmetic Act or licensed under the Public Health Service Act to permit the applicant to rely on certain existing scientific knowledge about the safety and effectiveness of the approved protein product" 18 . With the recent enactment of an approval pathway for such products, the term was changed to biosimilars 19 . However, whereas the new legislation in the United States foresees the licensure of biological products as biosimilar or interchangeable, the EU legislation and guidelines do not mention the issue of interchangeability, mainly because any decision on automatic substitution has to be made at the national In recent chemical analyses of various 'noninnovator epoetins' , significant differences (compared with the supposed originator product) with regard to physicochemical characteristics and potency were observed 6 , whereas almost superimposable quality characteristics were demonstrated for a 'biosimilar' epoetin 7 . The main difference between these two seemingly contradictory findings is that one paper 6 analyzed proteins that are not biosimilars, as we wish to define them, whereas the other article 7 analyzed a true biosimilar (Binocrit 8 ). We acknowledge that the authors in both publications used the terms in an appropriate manner. In addition, some of these noninnovator epoetins exhibited very high batch-tobatch variability, exceeding self-declared specifications for several batches 9, 10 or were found to be associated with severe adverse reactions (pure red cell aplasia) 11 .
In our opinion, some low molecular weight heparins already marketed outside the EU and the United States should also not be labeled biosimilars because it is not clear whether they were developed in a comparative manner 12 . Furthermore, different formulations of botulinum toxin A recently described by Wenzel et al. 13 do not qualify as true biosimilars because of obvious differences in physicochemical characteristics, doses and dosing regimens 13 .
Another misinterpretation of the biosimilar concept is to brand secondgeneration proteins-analogs with differences in the primary structure-as biosimilars. Our understanding of the term second-generation proteins are biologicals or biologics that have been structurally and/or functionally altered to gain an improved, or different, clinical performance. An example would be a chimeric monoclonal antibody and a subsequently developed fully human monoclonal antibody, directed against the same antigen or a cytokine product and its counterpart decorated with polyethylene glycol. As these would clearly exhibit differences in the structure of the active substance and different clinical behavior due to different potency or immunogenicity, the second-generation products cannot be biosimilar to each other.
The most striking misinterpretation of the term biosimilar was noted by one of us (C.K.S.) during a conference, where a physician expressed his doubts about biosimilars because "they may not even contain active substance. " Here the term biosimilar was obviously conflated with counterfeit medicine, which according to the in insulin-sensitive, normal-weight healthy people or individuals with type 1 diabetes mellitus than in those who are obese and have insulin-resistant type 2 diabetes. A valid conclusion on similarity can only be made based on reassurance that relevant differences would indeed have been detectable by the 'model' used in the clinical studies. This also implies that the clinical trial design may be different from that for a novel molecular entity and may also use different (clinical or pharmacodynamic), more sensitive endpoints.
Demonstration of equivalent (that is, clinically not showing relevant lower or higher) efficacy is needed to adopt the dose recommendations established for the reference product. In the case of lower potency, a higher dose would be needed to achieve the same effects as the reference product. In the case of higher potency, safety concerns could arise when using the dose(s) recommended for the reference product, especially for products with a narrow therapeutic margin. Relevant differences in efficacy would therefore contradict the assumption of similarity and would likely preclude extrapolation of efficacy and safety data to other indications of the reference product, particularly those with different dose requirements.
These points make it clear that, although a reduction in the data requirements is possible for biosimilars, the prelicensing data package is nevertheless substantial. Similarity in physicochemical characteristics is a prerequisite for a possible reduction in nonclinical and clinical data requirements. The amount of possible data reduction depends on how well the molecule can be characterized by state-of-the-art analytical methods, on observed or potential differences between the biosimilar and the reference product, and the clinical experience gained with the reference product and/or the substance class.
The above description outlines the requirements for the licensing of biosimilar medicinal products in the EU. But what of other types of nonbrand biologics that may not fall under this definition of biosimilars?
Various terms have emerged in different parts of the world for copy versions of original biological medicinal products, including biosimilars, follow-on biologicals/ biologics, subsequent-entry biologicals/ biologics, similar biopharmaceuticals, metoo biologicals/biologics, biogenerics or noninnovator proteins. In addition, different definitions of the same term in different geographical locations add to the semantic confusion.
level of individual EU member states. FDA guidelines defining the data requirements for biosimilar and interchangeable biologicals are awaited.
We believe that terminology covering biosimilars is important because demonstrated close resemblance to the reference product is a key feature of biosimilars with inherent implications that the prescribing physician must be able to rely upon. A proposal for a more precise terminology is provided in Table 1 . In conclusion, we would like to propose a narrow definition of biosimilars as follows:
A biosimilar is a copy version of an already authorized biological medicinal product with demonstrated similarity in physicochemical characteristics, efficacy and safety, based on a comprehensive comparability exercise.
We are open for scientific exchange on this topic with all stakeholders.
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Synergies between synthetic biology and metabolic engineering
To the Editor: Your focus issue on 'Synthetic Biology' (December 2009) highlighted some of the ambiguities in defining the fields of metabolic engineering and synthetic biology. Here we provide our interpretation of the scope of each of these fields and then provide suggestions for how they could be dovetailed synergistically to facilitate the design and construction of efficient cell factories.
Metabolic engineering has evolved into an area of research that encompasses detailed metabolic analyses with the objective of identifying targets for manipulation and directed genetic modification (through the use of recombinant DNA technology) for the improvement and/or design of cells. Improvement may focus on a range of different strategies, including enhancement of substrate range, production of novel products, increase of yield and productivity, and/or augmentation of cellular robustness (e.g., improved tolerance towards toxic compounds).
Recent years have also witnessed the emergence of synthetic biology, both as a means to reconstruct small, artificial biological systems (e.g., to assemble a novel biological regulon or oscillators that can be used to regulate gene expression in response to a specific input) 1 and as an approach for synthesizing DNA and complete chromosomes, as illustrated by the recent culmination of several decades of work attempting to reconstruct a complete bacterial genome 2 . In industrial biology, synthetic biology offers some tremendous opportunities to create cell factories tailormade for efficient production of fuels and chemicals.
In most cases, though, the design and construction of cell factories for use in industrial biology requires both synthetic biology and metabolic engineering (Fig. 1) . In many instances, a well-known, safe, platform cell factory is used as a chassis for production of a new chemical compound. The first step is to reconstruct a completely synthetic pathway in this cell factory and, thereafter, the regulation of the carbon fluxes is altered such that there is a sufficient flux toward the product of interest to allow an economically feasible process. There are several reasons why this combined approach is widely used in cell factory design.
